Endra life sciences and hepion pharmaceuticals partner to drive efficiencies in nash clinical trials

Hepion to include endra's taeus Ⓡ technology in phase 2b trial of crv431 ann arbor, mi and edison, nj / accesswire / march 18, 2021 / endra life sciences inc. (nasdaq:ndra), a pioneer of thermo acoustic enhanced ultrasound (taeus®), and hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical-stage biopharmaceutical company focused on ai-driven therapeutic drug development for the treatment of nash and liver disease, announced today the signing of a collaboration agreement to incorporate taeus as an add-on technology to support hepion's patient screening and biomarker measurement during the upcoming phase 2b study of crv431. "we are thrilled to partner with hepion pharmaceuticals in the further clinical development of crv431," said endra's chairman and chief executive officer francois michelon.
HEPA Ratings Summary
HEPA Quant Ranking